23S rRNA Inhibitors
4 drugsAbout 23S rRNA
The 23S rRNA is a crucial component of the bacterial ribosome, responsible for protein synthesis. Disrupting its function halts bacterial protein production, leading to cell death or growth inhibition, making it a valuable antibacterial target.
The demonstrated efficacy of drugs targeting 23S rRNA underscores its importance as a therapeutic target. Currently, there is no genetic evidence directly linking variations in 23S rRNA sequence to specific disease states.
Four small molecule drugs, including CLEOCIN, LINCOCIN, and their formulations, target 23S rRNA. These drugs, developed by Pfizer, were approved between 1964 and 1980 for various bacterial infections.
Top 23S rRNA Drugs
Pfizer is the only company with approved drugs targeting 23S rRNA.
High market concentration indicates potential entry barriers, requiring strong IP or novel mechanisms.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| CLEOCIN | PHARMACIA AND UPJOHN | 1980 | 1 |
23S rRNA Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets 23S rRNA, using small molecule modality.
Explore alternative modalities like oligonucleotides or peptides to differentiate from existing therapies.
23S rRNA Clinical Trials 54 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on 23S rRNA. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 10 | 8 | 1 | 1 | 89% |
| Phase 2 | 10 | 4 | 3 | 3 | 57% |
| Phase 3 | 13 | 12 | 0 | 1 | 100% |
| Phase 4 | 21 | 11 | 0 | 10 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
23S rRNA Drug Approval Timeline (1970 - 1970)
The first drug targeting 23S rRNA was approved in 1964, and the most recent in 1980.
The long gap since the last approval suggests saturation or challenges in developing new 23S rRNA-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 4 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 4-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 47 (17 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on 23S rRNA. A trial counts if an approved drug acting on 23S rRNA is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.